Radiation therapy and PD-1/PD-L1 blockade: the clinical development of an evolving anticancer combin...
Radiation therapy and PD-1/PD-L1 blockade: the clinical development of an evolving anticancer combination
About this item
Full title
Author / Creator
Publisher
England: BioMed Central Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: BioMed Central Ltd
Subjects
More information
Scope and Contents
Contents
Several inhibitors of programmed cell death-1 (PD-1) and programmed death ligand-1 (PD-L1) have been approved as a form of immunotherapy for multiple cancers. Ionizing radiation therapy (RT) has been shown to enhance the priming and effector phases of the antitumor T-cell response rendering it an attractive therapy to combine with PD-1/PD-L1 inhibi...
Alternative Titles
Full title
Radiation therapy and PD-1/PD-L1 blockade: the clinical development of an evolving anticancer combination
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_16c95f762a164a7697fa1d2032c8938e
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_16c95f762a164a7697fa1d2032c8938e
Other Identifiers
ISSN
2051-1426
E-ISSN
2051-1426
DOI
10.1186/s40425-018-0361-7
